<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846231</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.0 23February2021</org_study_id>
    <nct_id>NCT04846231</nct_id>
  </id_info>
  <brief_title>Supplements, Placebo, or Rosuvastatin Study</brief_title>
  <acronym>SPORT</acronym>
  <official_title>Supplements, Placebo, or Rosuvastatin Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A research study that is evaluating a low dose of an FDA approved statin medication in&#xD;
      comparison to several commercially available over the counter dietary supplements which are&#xD;
      marketed for cholesterol health. The study is comparing their effect on LDL cholesterol.&#xD;
      LDL-cholesterol is low-density cholesterol and is sometimes referred to as &quot;bad&quot; cholesterol.&#xD;
      Participants must live in Ohio and have a documented elevated LDL cholesterol level between&#xD;
      70-189mg/dL, must not currently be taking a statin or one of the dietary supplements included&#xD;
      in the trial. Participants willing to discontinue a prohibited supplement for 4 weeks prior&#xD;
      to enrollment will be allowed to participate. Trial participation is 4 weeks. Study&#xD;
      medication will be provided at no charge. There will be 2 visits which include a lab draw at&#xD;
      any Cleveland Clinic laboratory. Participants will be randomized (like a coin flip) to be in&#xD;
      one of 8 possible groups: Rosuvastatin, Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol,&#xD;
      Red yeast rice, or placebo. The study will enroll 200 participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Few well-controlled trials have studied the LDL-lowering effects of dozens of marketed&#xD;
      &quot;cholesterol health&quot; dietary supplements. Prior research suggests most U.S. consumers believe&#xD;
      cholesterol health supplements are safer than statins, and a majority of the public also&#xD;
      believe supplements are as effective, or more effective, than prescription statins.&#xD;
      Approximately one third of US adults who have been told they have elevated cholesterol are&#xD;
      using a supplement to provide heart health protection rather than a statin. This represents a&#xD;
      significant public health concern.&#xD;
&#xD;
      The purpose of this study is to evaluate the effect of select dietary supplements on&#xD;
      cholesterol health compared with a low dose of a statin.&#xD;
&#xD;
      The study is comparing their effect on LDL and HDL cholesterol and inflammatory markers.&#xD;
&#xD;
      A randomized, single blind study design will be used to evaluate rosuvastatin 5 mg. vs.&#xD;
      placebo and 6 commercially available over the counter supplements in a hierarchical testing&#xD;
      order. Each participant will take study medication/supplement for a total of 4 weeks.&#xD;
&#xD;
      The study will randomize primary prevention patients who are considered borderline and&#xD;
      intermediate risk for ASCVD based upon the 2018 Cholesterol Treatment Guidelines7 and are not&#xD;
      taking any of the studied medication/supplements at the time of randomization.&#xD;
&#xD;
      Participants must have a documented elevated LDL cholesterol level between 70-189mg/dL, must&#xD;
      not currently be taking a statin or one of the dietary supplements included in the trial.&#xD;
      Participants willing to discontinue a prohibited supplement for 4 weeks prior to enrollment&#xD;
      will be allowed to participate. Study medication will be provided at no charge. There will be&#xD;
      2 visits which include a lab draw at any Cleveland Clinic laboratory. Participants will be&#xD;
      randomized (like a coin flip) to be in one of 8 possible groups: Rosuvastatin, Fish oil,&#xD;
      Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice, or placebo. The study will enroll&#xD;
      200 participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">November 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 29, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible subjects will be randomized 1:1:1:1:1:1:1:1 to the study groups in a blinded fashion. There will be 25 subjects per study group. The total sample size will be 200 patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Subjects, investigator staff, persons performing the assessments, and the clinical trial team will be blinded to assigned study group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the LDL-C lowering of rosuvastatin with dietary supplements.</measure>
    <time_frame>The percent change in LDL-C for rosuvastatin 5 mg compared with dietary supplements after 4 weeks</time_frame>
    <description>The primary objective of this study is to compare the LDL lowering of rosuvastatin with the effect of six commonly used dietary supplements on cholesterol health.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in hsCRP for rosuvastatin vs dietary supplements.</measure>
    <time_frame>The percent change in high sensitivity C reactive protein (hsCRP) for rosuvastatin 5 mg and dietary supplements compared with placebo after 4 weeks.</time_frame>
    <description>Assess the effect of each supplement on inflammatory markers compared with rosuvastatin 5 mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in HDL-C, total cholesterol, and triglycerides for rosuvastatin vs dietary supplements.</measure>
    <time_frame>After 4 weeks</time_frame>
    <description>The percent change in HDL-C, total cholesterol, and triglycerides for each supplement compared with rosuvastatin.&#xD;
The percent change in HDL-C, total cholesterol, and triglycerides for each supplement compared with rosuvastatin.&#xD;
The percent change in HDL-C, total cholesterol, and triglycerides for each supplement compared with placebo.&#xD;
The percent change in HDL-C, total cholesterol, and triglycerides for each supplement compared with rosuvastatin. The percent change in HDL-C, total cholesterol, and triglycerides for each supplement compared with placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in HDL-C, total cholesterol, and triglycerides for placebo vs the dietary supplements.</measure>
    <time_frame>After 4 weeks</time_frame>
    <description>The percent change in HDL-C, total cholesterol, and triglycerides for each supplement compared with placebo.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>comparable to rosuvastatin 5 mg once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish Oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nature Made 2 soft gels per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cinnamon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1200mg, 2 capsules per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Garlique</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Manufactured by Focus Consumer Health Marketgate,1 tablet per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Turmeric</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bio Schwartz Turmeric Curcumin 1500 mg, 3 capsules per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plant Sterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nature Made CholestOff Plus, 2 soft gels twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Red Yeast Rice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arazo Nutrition 1200 mg, 2 capsules per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice</intervention_name>
    <description>Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).</description>
    <arm_group_label>Cinnamon</arm_group_label>
    <arm_group_label>Fish Oil</arm_group_label>
    <arm_group_label>Garlique</arm_group_label>
    <arm_group_label>Plant Sterol</arm_group_label>
    <arm_group_label>Red Yeast Rice</arm_group_label>
    <arm_group_label>Turmeric</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent must be obtained before any assessment is performed.&#xD;
&#xD;
          2. U.S. adults with primary hypercholesterolemia, 40-75 years of age.&#xD;
&#xD;
          3. Not currently taking statins or one of the dietary supplements included in the trial.&#xD;
             Patients willing to discontinue a prohibited supplement for 4 weeks prior to&#xD;
             enrollment will be allowed to participate.&#xD;
&#xD;
          4. LDL-cholesterol between 70 and 189 mg/dL.&#xD;
&#xD;
          5. Patients without diabetes mellitus and a 10-year risk of ASCVD between 5 and &lt;20%&#xD;
             using the pooled cohort risk equation. * Or Patients with diabetes mellitus in females&#xD;
             50-60 years of age or males 40-50 years of age with an LDL-C between 70-189 mg/dL and&#xD;
             with an ASCVD risk below 20%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 40 or &gt;75 years of age&#xD;
&#xD;
          2. Women who are pregnant, plan to become pregnant within the next 6 months, or are&#xD;
             breastfeeding.&#xD;
&#xD;
          3. Documented liver dysfunction or history of elevated LFTs indicating active liver&#xD;
             disease&#xD;
&#xD;
          4. Documented chronic renal dysfunction within the past two years defined as an&#xD;
             eGFR&lt;30mL/min/m2.&#xD;
&#xD;
          5. Known hypersensitivity to rosuvastatin or any supplement under investigation (i.e.&#xD;
             shellfish allergy, etc.).&#xD;
&#xD;
          6. Currently taking any prescription statin, or other prescription medication/supplements&#xD;
             to treat elevated cholesterol or triglycerides.&#xD;
&#xD;
          7. Currently taking a medication/supplement that has known interaction with rosuvastatin,&#xD;
             including fenofibrate, gemfibrozil, HIV medications, colchicine, cyclosporine,&#xD;
             warfarin, anti-viral medications to treat Hepatitis C, regorafenib, and darolutamide.&#xD;
&#xD;
          8. Are unwilling to discontinue prohibited dietary supplement(s) for 4 weeks prior to&#xD;
             participation or during the course of the trial. Other non-prohibited supplements will&#xD;
             be permitted if doses have been stable for at least 4 weeks.&#xD;
&#xD;
          9. Known cardiovascular disease including a history of prior MI, stroke/TIA, PAD or prior&#xD;
             revascularization procedures of the heart or vasculature (e.g. CABG, stenting, PCI&#xD;
             etc.).&#xD;
&#xD;
         10. Fasting Triglycerides &gt;200mg/dl.&#xD;
&#xD;
         11. In the opinion of the investigator, any other condition that will preclude&#xD;
             participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luke Laffin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Nissen, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Research Coordinator</last_name>
    <phone>216-444-3666</phone>
    <email>C5Rclinicaltrials@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luke Laffin, M.D.</last_name>
    <phone>216-444-3666</phone>
    <email>laffinl@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <email>C5Rclinicaltrials@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Luke Laffin</last_name>
      <email>laffinl@ccf.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LDL &amp; HDL Cholesterol, Statin, Dietary Supplements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Red yeast rice</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

